Odile Jaume has over two decades of molecular imaging and radiopharmaceuticals experience and a strong track record in international healthcare and technology commercialization. She brings a unique blend of field expertise and executive leadership allowing to design and execute growth strategies with a highly patient centric and industry-academia collaborative approach.

Ms. Jaume holds a MBA from UChicago USA and an engineering degree from UCL Belgium. She served in sales and product management at IBA and Siemens Healthineers as well as in start-up and business development of a series of organizations active in radiopharmaceuticals development and commercialization, including as President and COO of Telix Pharmaceuticals Europe.

Since June 2021 she is CEO of the International Centers for Precision Oncology (ICPO), a private non-profit foundation with mission to scale global patient access to Radiomolecular Precision Oncology.

Thanks to her entrepreneurial acumen and strong focus on purpose, Ms. Jaume develops and leads innovative strategic initiatives for ICPO at global scale, such as clinical centers optimization and creation, healthcare professionals’ education, community & scientific events, research grant management and non-profit fund raising.